D El-Maouche1,2, C E Dumitrescu3, P Andreopoulou4, R I Gafni2, B A Brillante2, N Bhattacharyya5, N S Fedarko6, M T Collins7. 1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 2. Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. 3. Division of Endocrinology, Alice Hyde Medical Center, Malone, NY, USA. 4. Endocrine Service, Department of Medicine, Hospital for Special Surgery, New York, NY, USA. 5. Thoracic and GI Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6. Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 7. Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. mcollins@dir.nidcr.nih.gov.
Abstract
UNLABELLED: There is growing need for a reliable assay for measuring fibroblast growth factor 23 (FGF23), a regulator of phosphorus and vitamin D. In this work, we analyze and compare the performance of three available assays, including the effect of temperature and time. This knowledge will allow for better understanding of FGF23 in the future. INTRODUCTION: Intact and C-terminal FGF23 (iFGF23 and cFGF23) concentrations are important in the diagnosis of hypo- and hyperphosphatemic diseases. The effects of temperature, storage, and specimen handling on FGF23 levels are not well known. We investigated the effects of various factors on plasma and serum measurement of FGF23 using three different assays. METHODS: Serum and plasma FGF23 were measured using three commercially available ELISA assays-two measuring iFGF23 and one measuring cFGF23. Samples from subjects with known FGF23 disorders were stored at 4, 22, and 37 °C and analyzed at different intervals up to 48 hours (h). A subset of samples underwent repeated freeze-thaw cycles, and samples frozen at -80 °C for up to 60 months were reanalyzed. The effect of adding a furin convertase inhibitor on FGF23 degradation was investigated using samples stored at 37 °C for 48 h. Intact FGF23 levels were measured from plasma samples of four different groups to test the correlation of the two assays. RESULTS: Plasma FGF23 levels were stable when stored at 4 and 22 °C for 48 h. Both plasma and serum FGF23 levels demonstrated relative stability after five freeze-thaw cycles. Long-term storage at -80 °C for 40 months induced some variability in FGF23 levels. The addition of a furin inhibitor did not affect FGF23 degradation. Intact FGF23 levels showed good correlation only at the upper limit of the assay range when comparing the two assays. CONCLUSIONS: Sample type, handling, and choice of assay are factors that affect FGF23 levels and should be considered when measuring this hormone.
UNLABELLED: There is growing need for a reliable assay for measuring fibroblast growth factor 23 (FGF23), a regulator of phosphorus and vitamin D. In this work, we analyze and compare the performance of three available assays, including the effect of temperature and time. This knowledge will allow for better understanding of FGF23 in the future. INTRODUCTION: Intact and C-terminal FGF23 (iFGF23 and cFGF23) concentrations are important in the diagnosis of hypo- and hyperphosphatemic diseases. The effects of temperature, storage, and specimen handling on FGF23 levels are not well known. We investigated the effects of various factors on plasma and serum measurement of FGF23 using three different assays. METHODS: Serum and plasma FGF23 were measured using three commercially available ELISA assays-two measuring iFGF23 and one measuring cFGF23. Samples from subjects with known FGF23 disorders were stored at 4, 22, and 37 °C and analyzed at different intervals up to 48 hours (h). A subset of samples underwent repeated freeze-thaw cycles, and samples frozen at -80 °C for up to 60 months were reanalyzed. The effect of adding a furin convertase inhibitor on FGF23 degradation was investigated using samples stored at 37 °C for 48 h. Intact FGF23 levels were measured from plasma samples of four different groups to test the correlation of the two assays. RESULTS: Plasma FGF23 levels were stable when stored at 4 and 22 °C for 48 h. Both plasma and serum FGF23 levels demonstrated relative stability after five freeze-thaw cycles. Long-term storage at -80 °C for 40 months induced some variability in FGF23 levels. The addition of a furin inhibitor did not affect FGF23 degradation. Intact FGF23 levels showed good correlation only at the upper limit of the assay range when comparing the two assays. CONCLUSIONS: Sample type, handling, and choice of assay are factors that affect FGF23 levels and should be considered when measuring this hormone.
Authors: Kentaro Kato; Charlotte Jeanneau; Mads Agervig Tarp; Anna Benet-Pagès; Bettina Lorenz-Depiereux; Eric Paul Bennett; Ulla Mandel; Tim M Strom; Henrik Clausen Journal: J Biol Chem Date: 2006-04-25 Impact factor: 5.157
Authors: Azarmindokht Khosravi; Carolee M Cutler; Marilyn H Kelly; Richard Chang; Richard E Royal; Richard M Sherry; Felasfa M Wodajo; Neal S Fedarko; Michael T Collins Journal: J Clin Endocrinol Metab Date: 2007-03-20 Impact factor: 5.958
Authors: Young H Lim; Diana Ovejero; Jeffrey S Sugarman; Cynthia M C Deklotz; Ann Maruri; Lawrence F Eichenfield; Patrick K Kelley; Harald Jüppner; Michael Gottschalk; Cynthia J Tifft; Rachel I Gafni; Alison M Boyce; Edward W Cowen; Nisan Bhattacharyya; Lori C Guthrie; William A Gahl; Gretchen Golas; Erin C Loring; John D Overton; Shrikant M Mane; Richard P Lifton; Moise L Levy; Michael T Collins; Keith A Choate Journal: Hum Mol Genet Date: 2013-09-04 Impact factor: 6.150
Authors: Edward R Smith; Martin L Ford; Laurie A Tomlinson; Gary Weaving; Bernard F Rocks; Chakravarthi Rajkumar; Stephen G Holt Journal: Clin Chim Acta Date: 2011-02-12 Impact factor: 3.786
Authors: Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske Journal: Matrix Biol Date: 2004-11 Impact factor: 11.583
Authors: Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins Journal: Trends Endocrinol Metab Date: 2012-08-24 Impact factor: 12.015
Authors: Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley Journal: Br J Clin Pharmacol Date: 2018-07-17 Impact factor: 4.335
Authors: Charles Ginsberg; Timothy E Craven; Michel B Chonchol; Alfred K Cheung; Mark J Sarnak; Walter T Ambrosius; Anthony A Killeen; Kalani L Raphael; Udayan Y Bhatt; Jing Chen; Glenn M Chertow; Barry I Freedman; Suzanne Oparil; Vasilios Papademetriou; Barry M Wall; Clinton B Wright; Joachim H Ix; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2018-11-13 Impact factor: 8.237
Authors: Anna Jovanovich; Charles Ginsberg; Zhiying You; Ronit Katz; Walter T Ambrosius; Dan Berlowitz; Alfred K Cheung; Monique Cho; Alexandra K Lee; Henry Punzi; Shakaib Rehman; Christianne Roumie; Mark A Supiano; Clinton B Wright; Michael Shlipak; Joachim H Ix; Michel Chonchol Journal: J Am Geriatr Soc Date: 2020-12-01 Impact factor: 5.562